Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study

Diabetic macular edema (DME) is an increasingly frequent cause of visual impairment throughout the world because of the rising global prevalence of diabetes.1 In the U.S., it has been estimated that 3.8% of adults ages 40 years and older with diabetes mellitus have DME.2 A critical challenge is to address the refractory nature of the disease. Since the 1980s, standard of care for DME had been focal and/or grid laser photocoagulation of leaking microaneurysms and areas of retinal thickening to reduce the rate of further loss in vision.3 However, within the past few years, treatment options

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - June 21, 2018 Category: Opthalmology Authors: Michael A. Singer, MD Source Type: research